SCYNEXIS reported FY 2025 total revenue of USD 20.6 million (up 449.9%), including USD 19.2 million in license agreement revenue (up 411.4%) tied primarily to its GSK license agreement and a USD 17.2 million cumulative catch-up recognized under an October 2025 memorandum of understanding. Product revenue, net was USD 1.4 million, reflecting a change in estimate related to prior-period BREXAFEMME recall revenue. FY 2025 net loss was USD 8.6 million (down 59.6%), with R&D expense of USD 22.3 million (down 15.6%) and SG&A expense of USD 14.4 million. SCYNEXIS ended FY 2025 with USD 56.3 million in cash, cash equivalents and investments, and said it expects its capital resources to fund operations for at least 12 months from issuance of the financial statements. On the pipeline, SCYNEXIS said it completed single and multiple ascending dose portions of a Phase 1 oral SCY-247 study in 88 healthy subjects, reporting the drug was well tolerated with no serious or severe treatment-emergent adverse events and generally dose-proportional pharmacokinetics up to 400 mg once daily. The company also said it initiated a Phase 1 study of intravenous SCY-247 in Q1 2026 and plans a Phase 2 proof-of-concept study in 2026 in patients with invasive candidiasis. On ibrexafungerp/BREXAFEMME, SCYNEXIS said it agreed with GSK to wind down and terminate the Phase 3 MARIO study and received one-time, non-refundable payments totaling USD 24.8 million in November 2025; it completed transfer of the BREXAFEMME NDA to GSK in November 2025, and GSK anticipates FDA interactions in 2026 to discuss a U.S. relaunch for VVC and rVVC. Separately, SCYNEXIS said Nasdaq granted it an extension until June 15, 2026 to regain compliance with the USD 1.00 minimum bid price requirement, and it may pursue a reverse stock split if needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-26-000007), on March 04, 2026, and is solely responsible for the information contained therein.